CompoAtlas

MAGNÉSIUM MARIN + TRANSIT

Food supplement declared in France, declaration No 2018-2-391

MAGNÉSIUM MARIN + TRANSIT (BIOTECHNIE) is a food supplement declared in France. Status: withdrawn from the market on 31 March 2021. 1 point in its composition requires a check (prohibited substance, dose or novel food). 2 rules of use apply to its ingredients (limits and warnings).

Brand
BIOTECHNIE
Food business operator placing the product on the market
COSMEDIET - BIOTECHNIE
Status
Withdrawn from the market on 31 March 2021
Form
Tablet
Daily dose
2 comprimés
Not recommended (according to the manufacturer)
Breastfeeding women, Children (under 12), Pregnant women, Prolonged use
Objectives stated by the manufacturer (these are not authorised claims)
Digestion

Declaration 206643, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Althaea officinalis L.RacineExtrait sec aqueux125 mg
Tanacetum parthenium (L.) Sch.Bip.Parties aériennesExtrait sec hydroalcoolique50 mg
Rheum palmatum L.Organes souterrainsPoudre (de plantes séchées ou broyées)50 mg
Rheum officinale Baill.Organes souterrainsPoudre (de plantes séchées ou broyées)50 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Oxyde de magnésiumMagnésium250 mg300 mg
Carbonate de magnésiumMagnésium250 mg300 mg

Additives

E460, E341, E470b

Other ingredients

Cosse de riz

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Déconseillé aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes. Ne pas utiliser de façon prolongée. La supplémentation en magnésium peut provoquer des effets laxatifs chez certaines personnes.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Althaea officinalis L.
    Read the warning, when it applies and the studies cited

    Marshmallow - ALTHAEA OFFICINALIS - Root

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Health Canada monograph dated 19 December 2025

    MARSHMALLOW - ALTHAEA OFFICINALIS - LEAF

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Health Canada monograph dated 29 November 2024

  • Tanacetum parthenium (L.) Sch.Bip.
    Read the warning, when it applies and the studies cited

    FEVERFEW - TANACETUM PARTHENIUM

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).

    Sources cited by Health Canada (2)
    • Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).

    Sources cited by Health Canada (1)
    • Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.

    Contraindications

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.

    Do not use if you are pregnant or breastfeeding (EMA 2020).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).

    Sources cited by Health Canada (2)
    • Hausen BM. A 6-year experience with compositae mix. American Journal of Contact Dermatitis 1996;7(2):94-99. PubMed
    • Paulsen E, Anderson KE and Hausen BM. Sensitization and cross-reaction patterns in Danish Compositae-allergic patients. Contact Dermatitis 2001;45(4):197-204. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).

    Sources cited by Health Canada (3)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
    • Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : BIOTECHNIE

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line